Humacyte Files 8-K, Nasdaq Listings Confirmed

Ticker: HUMAW · Form: 8-K · Filed: Sep 18, 2025 · CIK: 1818382

Humacyte, Inc. 8-K Filing Summary
FieldDetail
CompanyHumacyte, Inc. (HUMAW)
Form Type8-K
Filed DateSep 18, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001, $11.50, $50.0 million, $12.5 million, $95.5 m
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, listing-status, company-update

Related Tickers: HUMA, HUMAW

TL;DR

HUMA & HUMAW still Nasdaq listed, nothing new.

AI Summary

Humacyte, Inc. filed an 8-K on September 17, 2025, reporting its status as an emerging growth company. The filing confirms its common stock trades under the symbol HUMA and its redeemable warrants under HUMAW on The Nasdaq Stock Market LLC. The company's principal executive offices are located in Durham, NC.

Why It Matters

This filing serves as a routine update, confirming the company's listing status and basic corporate information on file with the SEC.

Risk Assessment

Risk Level: low — This is a standard 8-K filing primarily confirming existing information and company status.

Key Players & Entities

  • Humacyte, Inc. (company) — Registrant
  • September 17, 2025 (date) — Date of earliest event reported
  • HUMA (stock_symbol) — Common Stock Trading Symbol
  • HUMAW (stock_symbol) — Redeemable Warrants Trading Symbol
  • The Nasdaq Stock Market LLC (company) — Exchange where securities are registered
  • Durham, NC (location) — Address of principal executive offices

FAQ

What is the primary purpose of this 8-K filing for Humacyte, Inc.?

The primary purpose is to report the date of the earliest event, confirm its status as an emerging growth company, and list its registered securities and exchanges.

On which exchange are Humacyte, Inc.'s common stock and warrants traded?

Humacyte, Inc.'s common stock (HUMA) and redeemable warrants (HUMAW) are traded on The Nasdaq Stock Market LLC.

What is the trading symbol for Humacyte, Inc.'s common stock?

The trading symbol for Humacyte, Inc.'s common stock is HUMA.

What is the exercise price for Humacyte, Inc.'s redeemable warrants?

The redeemable warrants are exercisable at an exercise price of $11.50 per whole warrant.

Where are Humacyte, Inc.'s principal executive offices located?

Humacyte, Inc.'s principal executive offices are located at 2525 East North Carolina Highway 54, Durham, NC 27713.

Filing Stats: 846 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2025-09-17 21:45:02

Key Financial Figures

  • $0.0001 — h registered Common Stock, par value $0.0001 per share HUMA The Nasdaq Stock Mar
  • $11.50 — of Common Stock at an exercise price of $11.50 HUMAW The Nasdaq Stock Market LLC
  • $50.0 million — the Amendment, the Company will make a $50.0 million repayment under the Purchase Agreement,
  • $12.5 million — he Company will be required to maintain $12.5 million in such account. Further, the Company w
  • $95.5 m — ion at a discounted repurchase price of $95.5 million, so long as it is exercised on or
  • $7.5 million — on or prior to December 31, 2025, up to $7.5 million of which may be satisfied through the i

Filing Documents

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement As part of a planned refinancing of certain debt obligations, on September 17, 2025, Humacyte, Inc. (the "Company") and Humacyte Global, Inc., a wholly owned subsidiary of the Company ("Global"), entered into Amendment No. 2 to the Revenue Interest Purchase Agreement (the "Amendment") with TPC Investments III LP and TPC Investment Solutions LP (collectively, the "Purchasers") and Hook SA LLC, as agent for the Purchasers (the "Agent"), to amend the Revenue Interest Purchase Agreement, dated as of May 12, 2023, as amended (the "Purchase Agreement"), among the Company, Global, the Purchasers and the Agent. In connection with the Amendment, the Company will make a $50.0 million repayment under the Purchase Agreement, funded from the restricted cash currently maintained for the benefit of the Agent. Additionally, the Company and Global will no longer be obligated to maintain $50.0 million of restricted cash in an account for the benefit of the Agent unless the Purchase Agreement has not been repaid in full by December 31, 2025, at which point the Company will be required to maintain $12.5 million in such account. Further, the Company will now be permitted, at its option, to exercise its call option at a discounted repurchase price of $95.5 million, so long as it is exercised on or prior to December 31, 2025, up to $7.5 million of which may be satisfied through the issuance of shares of the Company's common stock, par value $0.0001 per share, subject to the satisfaction of certain conditions. The Amendment also contains customary representations, warranties and agreements by the Company and customary closing conditions. The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, which is attached as Exhibit 10.1 hereto and is incorporated herein by reference. This Current Report on Form 8-K is neither an offer to sell nor a solicitation of an offer to buy a

03. Creation of a Direct Financial Obligation or an Obligation

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The disclosure set forth above under the Item 1.01 is incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Amendment No. 2 to the Revenue Interest Purchase Agreement, dated as of September 17, 2025, by and among Humacyte Global, Inc., Humacyte, Inc. and TPC Investments III LP and TPC Investment Solutions LP and Hook SA LLC. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HUMACYTE, INC. Date: September 17, 2025 By: /s/ Dale A. Sander Name: Dale A. Sander Title: Chief Financial Officer, Chief Corporate Development Officer and Treasurer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.